Mustang Bio, Inc. (NASDAQ:MBIO – Get Free Report) was down 4.8% during trading on Friday . The stock traded as low as $2.71 and last traded at $2.78. Approximately 75,212 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 643,709 shares. The stock had previously closed at $2.92.
Mustang Bio Stock Performance
The business has a 50-day simple moving average of $7.84 and a two-hundred day simple moving average of $11.65. The stock has a market cap of $2.67 million, a price-to-earnings ratio of -0.04 and a beta of 1.73.
Mustang Bio (NASDAQ:MBIO – Get Free Report) last announced its quarterly earnings data on Friday, November 8th. The company reported ($2.00) earnings per share for the quarter, beating the consensus estimate of ($6.50) by $4.50. On average, analysts expect that Mustang Bio, Inc. will post -35 earnings per share for the current fiscal year.
About Mustang Bio
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Read More
- Five stocks we like better than Mustang Bio
- Best Stocks Under $10.00
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- How to Calculate Options Profits
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- What is Put Option Volume?
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.
